Cambridge Investment Research Advisors
ORMP icon

Cambridge Investment Research Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,372
Closed -$40K – 3260
2023
Q1 		$40K Buy
18,372
+6,188
+51% +$19.7K ﹤0.01% 3060
2022
Q4 		$147K Sell
12,184
-2,000
-14% -$15.5K ﹤0.01% 2839
2022
Q3 		$92K Buy
14,184
+3,000
+27% +$24.3K ﹤0.01% 2873
2022
Q2 		$51K Buy
+11,184
New +$59.8K ﹤0.01% 2941

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cambridge Investment Research Advisors's ORMP Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q2 2023, closing a stake of 18,372 shares — an estimated $40K sold.

Cambridge Investment Research Advisors first reported a position in ORMP in Q2 2022 and held it in 4 quarters. The position peaked at $147K in Q4 2022. 50 funds tracked by Wall St. Rank hold ORMP as of Q2 2023.

  • Cambridge Investment Research Advisors reported no remaining Oramed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 18,372 Oramed Pharmaceuticals shares in Q2 2023, an estimated $40K.
  • Cambridge Investment Research Advisors first reported a position in Oramed Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Oramed Pharmaceuticals position peaked at $147K in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.